NASDAQ:OVID

Ovid Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy OVID

*Your capital is at risk

$2.40

-0.0800 (-3.23%)

At Close: Jun 05, 2026

Ovid Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 94.22. In total, the insiders bought 15.95M and sold 39.88K OVID shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	94.22
● Buy	15.95M shares
● Sell	39.88K shares
92% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Feb 26, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 94.22. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (92% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 07, 2026 Buy	Common Stock A-Award	Fitzgerald Kevin Joseph Director	Director	17 578 Value: $45.0K
Apr 07, 2026 Buy	Common Stock A-Award	Friedman Bart Director	Director	8 789 Value: $22.5K
Apr 07, 2026 Buy	Common Stock A-Award	Papadopoulos Stelios Director	Director	17 578 Value: $45.0K
Mar 23, 2026 Buy	Series A Warrant (right to buy) M-Exempt	Levin Jeremy M Executive Chairman	CEO / President	47 333 Value: $66.3K
Mar 23, 2026 Buy	Common Stock M-Exempt	Levin Jeremy M Executive Chairman	CEO / President	47 333 Value: $66.3K
Feb 26, 2026 Buy	Common Stock A-Award	Rona Jeffrey A Cbfo	Officer	68 125 Value: $112.4K
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Duncan Barbara Gayle Director	Director	65 000 Value: $107.3K
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Friedman Bart Director	Director	65 000 Value: $107.3K
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Alexander Margaret A. President And CEO	CEO / President	1 435 000 Value: $2.37M
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Papadopoulos Stelios Director	Director	65 000 Value: $107.3K
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Levin Jeremy M Director	Director	957 000 Value: $1.58M
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Fitzgerald Kevin Joseph Director	Director	65 000 Value: $107.3K
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Bernstein Karen Director	Director	65 000 Value: $107.3K
Feb 26, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Rona Jeffrey A Cbfo	Officer	408 750 Value: $674.4K
Feb 23, 2026 Sell	Common Stock S-Sale	Alexander Margaret A. President And CEO	CEO / President	11 656 Value: $16.9K
Feb 23, 2026 Sell	Common Stock S-Sale	Rona Jeffrey A Cbfo	Officer	8 541 Value: $12.4K
Jan 04, 2026 Buy	Employee Stock Option (right to buy) A-Award	Alexander Margaret A. President And CEO	CEO / President	890 000 Value: $1.57M
Dec 15, 2025 Buy	Common Stock C-Conversion	Levin Jeremy M CEO	CEO / President	71 000 Value: $111.5K
Dec 15, 2025 Sell	Series B Convertible Preferred Stock C-Conversion	Levin Jeremy M CEO	CEO / President	71 Value: $0
Dec 11, 2025 Buy	Series A Warrant (right to buy) P-Purchase	Levin Jeremy M CEO	CEO / President	47 333 Value: $66.3K
Dec 11, 2025 Buy	Series B Warrant (right to buy) P-Purchase	Levin Jeremy M CEO	CEO / President	35 500 Value: $49.7K
Dec 11, 2025 Buy	Series B Convertible Preferred Stock P-Purchase	Levin Jeremy M CEO	CEO / President	71 Value: $117
Dec 08, 2025 Sell	Series A Convertible Preferred Stock C-Conversion	Takeda Pharmaceutical Co Ltd 10 Percent Owner	10% Owner	1 250 Value: $0
Dec 08, 2025 Buy	Common Stock C-Conversion	Takeda Pharmaceutical Co Ltd 10 Percent Owner	10% Owner	1 250 000 Value: $1.98M
Mar 03, 2025 Buy	Stock Option (right to buy) A-Award	Papadopoulos Stelios Director	Director	90 000 Value: $44.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OVID THERAPEUTICS INC

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule...

Read Full Profile Here